Bong Chul Chu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bong Chul Chu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Karen Smoyer Tomic
Oxford PharmaGenesis, Newtown, USA
2 shared publications - Niranjana Kowlessar
Truven Health Analytics, Bethesda, USA
2 shared publications - Rita Vandivort-Warren
Health Resources and Services Administration, Rockville, USA
2 shared publications - Tami L. Mark
Truven Health Analytics, 7700 Old Georgetown Road, Bethesda, MD 20814
2 shared publications - David R Diakun
Truven Health Analytics, Bethesda, MD, USA
1 shared publication - John H. Krege
Eli Lilly and Company, Indianapolis, IN, USA
1 shared publication
Latest Publications
- Open Access
- 23 March 2013
- Published by Springer Nature in BMC Women's Health
- Vol. 13 (1) , 15
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer. A definitive study comparing the fracture effectiveness and rate of breast cancer for raloxifene and alendronate has not been published. The purpose of this retrospective cohort study was to evaluate fracture and breast cancer rates among patients treated with raloxifene or alendronate.
- 23 March 2013
- Published by Springer Nature in BMC Women's Health
- Vol. 13 (1) , 15
Open AccessFractures in women treated with raloxifene or alendronate: a retrospective database analysis
Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer. A definitive study comparing the fracture effectiveness and rate of breast cancer for raloxifene and alendronate has not been published. The purpose of this retrospective cohort study was to evaluate fracture and breast cancer rates among patients treated with raloxifene or alendronate.
- 21 February 2013
- Published by Springer Nature in The Journal of Behavioral Health Services & Research
- Vol. 40 (2) , 207-221
Hospital Readmission Among Medicaid Patients with an Index Hospitalization for Mental and/or Substance Use Disorder
Hospital readmission rates are increasingly used as a performance indicator. Whether they are a valid, reliable, and actionable measure for behavioral health is unknown. Using the MarketScan Multistate Medicaid Claims Database, this study examined hospital- and patient-level predictors of behavioral health readmission rates. Among hospitals with at least 25 annual admissions, the median behavioral health readmission rate was 11% (10th percentile, 3%; 90th percentile, 18%). Increased follow-up at community mental health centers was associated with lower probabilities of readmission, although follow-up with other types of providers was not significantly associated with hospital readmissions. Hospital average length of stay was positively associated with lower readmission rates; however, the effect size was small. Patients with a prior inpatient stay, a substance use disorder, psychotic illness, and medical comorbidities were more likely to be readmitted. Additional research is needed to further understand how the provision of inpatient services and post-discharge follow-up influence readmissions.
- 21 February 2013
- Published by Springer Nature in The Journal of Behavioral Health Services & Research
- Vol. 40 (2) , 207-221
Hospital Readmission Among Medicaid Patients with an Index Hospitalization for Mental and/or Substance Use Disorder
Hospital readmission rates are increasingly used as a performance indicator. Whether they are a valid, reliable, and actionable measure for behavioral health is unknown. Using the MarketScan Multistate Medicaid Claims Database, this study examined hospital- and patient-level predictors of behavioral health readmission rates. Among hospitals with at least 25 annual admissions, the median behavioral health readmission rate was 11% (10th percentile, 3%; 90th percentile, 18%). Increased follow-up at community mental health centers was associated with lower probabilities of readmission, although follow-up with other types of providers was not significantly associated with hospital readmissions. Hospital average length of stay was positively associated with lower readmission rates; however, the effect size was small. Patients with a prior inpatient stay, a substance use disorder, psychotic illness, and medical comorbidities were more likely to be readmitted. Additional research is needed to further understand how the provision of inpatient services and post-discharge follow-up influence readmissions.